Literature DB >> 21208588

Emotional experience and estimates of D2 receptor occupancy in psychotic patients treated with haloperidol, risperidone, or olanzapine: an experience sampling study.

Johan Lataster1, Jim van Os, Lieuwe de Haan, Viviane Thewissen, Maarten Bak, Tineke Lataster, Mariëlle Lardinois, Philippe A G E Delespaul, Inez Myin-Germeys.   

Abstract

OBJECTIVE: Blockade of dopamine D(2) receptors is thought to mediate the therapeutic effects of antipsychotic medication but may also induce social indifference. As antipsychotic drugs differ in D(2) receptor binding, "tight" and "loose" binding drugs may be hypothesized to differentially affect emotional experience. The present study investigates the differential effects of relatively tight versus looser binding drugs on the experience of emotions in the realm of daily life.
METHOD: We assessed positive and negative affect in the daily life of 109 patients with a DSM-IV diagnosis of psychotic disorder who were currently taking antipsychotic medication by using the experience sampling method (a structured diary technique). Antipsychotic medication was classified as loose (olanzapine; n = 35) or tight (haloperidol, risperidone; n = 74) binding, based on the drug's dissociation constants at the D(2) receptor. The study was conducted from 2007 to 2008.
RESULTS: Multilevel analyses showed a significant interaction between binding group (loose vs tight) and D(2) receptor occupancy estimates with regard to the experience of positive (P = .008) and negative (P = .019) affect. For tight-binding-agent users, a significant association was found between D(2) receptor binding estimates and both positive affect (P = .040) and negative affect (P = .0001) in the flow of daily life, with increasing levels of estimated D(2) receptor occupancy being associated with decreased feelings of positive affect and increased feelings of negative affect. For loose-binding-agent users, no such association was apparent. These associations were only partly mediated by clinical symptoms.
CONCLUSIONS: These findings add ecological validity to previous laboratory findings showing an association between D(2) receptor occupancy and emotional experience. © Copyright 2011 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21208588     DOI: 10.4088/JCP.09m05466yel

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  12 in total

Review 1.  Revisiting the Concept of Subjective Tolerability to Antipsychotic Medications in Schizophrenia and its Clinical and Research Implications: 30 Years Later.

Authors:  A George Awad
Journal:  CNS Drugs       Date:  2019-01       Impact factor: 5.749

2.  Psychotic exacerbation and emotional dampening in the daily life of patients with schizophrenia switched to aripiprazole therapy: a collection of standardized case reports.

Authors:  Johan Lataster; Inez Myin-Germeys; Marieke Wichers; Philippe A E G Delespaul; J van Os; Maarten Bak
Journal:  Ther Adv Psychopharmacol       Date:  2011-10

3.  Experience sampling methodology in mental health research: new insights and technical developments.

Authors:  Inez Myin-Germeys; Zuzana Kasanova; Thomas Vaessen; Hugo Vachon; Olivia Kirtley; Wolfgang Viechtbauer; Ulrich Reininghaus
Journal:  World Psychiatry       Date:  2018-06       Impact factor: 49.548

4.  Negative affect predicts social functioning across schizophrenia and bipolar disorder: Findings from an integrated data analysis.

Authors:  Tyler B Grove; Ivy F Tso; Jinsoo Chun; Savanna A Mueller; Stephan F Taylor; Vicki L Ellingrod; Melvin G McInnis; Patricia J Deldin
Journal:  Psychiatry Res       Date:  2016-06-25       Impact factor: 3.222

5.  Preliminary evidence that negative symptom severity relates to multilocus genetic profile for dopamine signaling capacity and D2 receptor binding in healthy controls and in schizophrenia.

Authors:  Sarah A Eisenstein; Ryan Bogdan; Ling Chen; Stephen M Moerlein; Kevin J Black; Joel S Perlmutter; Tamara Hershey; Deanna M Barch
Journal:  J Psychiatr Res       Date:  2016-11-17       Impact factor: 4.791

6.  Relationship between subjective well-being and aripiprazole: an [11C]raclopride PET study.

Authors:  Seoyoung Kim; Elena Younhye Ock; Jun Soo Kwon; Euitae Kim
Journal:  Sci Rep       Date:  2022-07-15       Impact factor: 4.996

7.  Testing an mHealth momentary assessment Routine Outcome Monitoring application: a focus on restoration of daily life positive mood states.

Authors:  Jim van Os; Philippe Delespaul; Daniela Barge; Roberto P Bakker
Journal:  PLoS One       Date:  2014-12-16       Impact factor: 3.240

8.  Behavioral and emotional adverse events of drugs frequently used in the treatment of bipolar disorders: clinical and theoretical implications.

Authors:  Alejandro Szmulewicz; Cecilia Samamé; Pablo Caravotta; Diego J Martino; Ana Igoa; Diego Hidalgo-Mazzei; Francesc Colom; Sergio A Strejilevich
Journal:  Int J Bipolar Disord       Date:  2016-02-16

Review 9.  Lurasidone in the Treatment of Bipolar Depression: Systematic Review of Systematic Reviews.

Authors:  Michele Fornaro; Domenico De Berardis; Giampaolo Perna; Marco Solmi; Nicola Veronese; Laura Orsolini; Elisabetta Filomena Buonaguro; Felice Iasevoli; Cristiano André Köhler; André Ferrer Carvalho; Andrea de Bartolomeis
Journal:  Biomed Res Int       Date:  2017-05-09       Impact factor: 3.411

10.  Evidence that a psychopathology interactome has diagnostic value, predicting clinical needs: an experience sampling study.

Authors:  Jim van Os; Tineke Lataster; Philippe Delespaul; Marieke Wichers; Inez Myin-Germeys
Journal:  PLoS One       Date:  2014-01-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.